Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allicor for Multifocal Atherosclerosis After Revascularization
NCT05813171Phase 4Unknown
- Sponsor
- Institute for Atherosclerosis Research
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by Institute for Atherosclerosis Research. Primary endpoints: Frequency of fatal cardiovascular events at 12 months, Frequency of clinically significant cardiovascular events at 12 months and 1 more. Status: unknown.
Beyond the preview
Go deeper on NCT05813171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813171.